[Effects of a massive dosage of methotrexate and leucovorin rescue therapy on acute leukemia and malignant lymphoma].
The cooperative study group, consisting of 11 institutes, conducted a study by the high-dose methotrexate (MTX) with citrovorum factor (CF) rescue therapy on acute leukemia and malignant lymphoma that were resistant to other anti-cancer chemotherapy. In acute leukemia the rates of complete remission (CR) and partial remission (PR) were 16.7% and 26.7%, respectively, and in malignant lymphoma the response rate (excellent plus good response) was 38.9%. This therapy would be safely carried out by alkalinization of urine and adequate hydration under sufficient clinical surveillance. From the results of the present study, high-dose MTX-CF therapy seems to be one of effective regimens for acute leukemia and malignant lymphoma that are resistant to the conventional doses of MTX or other anti--cancer agents. Also, with this therapy, treatment or prophylaxis of symptoms of central nervous system and of other pharmacological sanctuaries can be expected, which may be one of the useful points of H-MTX-CF therapy.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage*; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism
D002955:Leucovorin; D008727:Methotrexate